Reviewed Mar 2026 | PubMed sources
Active Market
Netherlands is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Ipamorelin vs Sermorelin: Head-to-Head Comparison

Ipamorelin works on the ghrelin receptor while sermorelin works on the GHRH receptor — two different arms of GH release. Sermorelin has a longer clinical history and was previously FDA-approved for pediatric GH deficiency. Ipamorelin provides cleaner pulses while sermorelin mimics the body's natural GHRH signaling.

Approved Comparison Routing

Approved options in this comparison

A
Sermorelin

Sermorelin is currently modeled on this site as an approved treatment path for: Diagnosis and treatment of growth hormone deficiency in children. Brand names in the current dataset: Geref.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Sermorelin with a provider?

Sermorelin is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Side-by-Side Comparison

DimensionIpamorelinSermorelin
Evidence LevelPhase II clinical trialsFormerly FDA-approved; extensive clinical history
FDA StatusNot approvedPreviously FDA-approved (withdrawn for commercial reasons, not safety)
MechanismGhrelin receptor (GHS-R1a) agonistGHRH receptor agonist (mimics natural GHRH)
Side EffectsMinimalInjection site pain, facial flushing, headache
Half-Life~2 hours~10-20 minutes (very short)
Primary UseBody composition, anti-agingGH deficiency, anti-aging
Evidence Level
Ipamorelin
Phase II clinical trials
Sermorelin
Formerly FDA-approved; extensive clinical history
FDA Status
Ipamorelin
Not approved
Sermorelin
Previously FDA-approved (withdrawn for commercial reasons, not safety)
Mechanism
Ipamorelin
Ghrelin receptor (GHS-R1a) agonist
Sermorelin
GHRH receptor agonist (mimics natural GHRH)
Side Effects
Ipamorelin
Minimal
Sermorelin
Injection site pain, facial flushing, headache
Half-Life
Ipamorelin
~2 hours
Sermorelin
~10-20 minutes (very short)
Primary Use
Ipamorelin
Body composition, anti-aging
Sermorelin
GH deficiency, anti-aging

Peptide Overviews

Ipamorelin

BHuman Studies

Ipamorelin is a selective growth hormone secretagogue that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin levels.

Growth Hormone SecretagoguesNot Approved
View full Ipamorelin profile →

Sermorelin

AFDA Approved

Sermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies.

Growth Hormone SecretagoguesFDA Approved
View full Sermorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Ipamorelin vs Sermorelin: FAQ